Weight-loss medications such as Ozempic and Mounjaro, which have ushered in a new era in the war on obesity, are being scrutinized for potential serious side effects, even as new research suggests they could offer protection against some cancers. Two significant areas of concern have emerged: a potential link to increased kidney cancer risk and widespread reports of dental health deterioration, often dubbed 'Ozempic teeth'.

A comprehensive study, the largest of its kind, tracked nearly 44,000 overweight and obese individuals taking slimming injections for up to ten years. Published in JAMA Oncology, the research revealed a complex picture. While the drugs were associated with a 17 percent lower overall risk of cancer, including significant reductions in ovarian, womb, and certain brain tumours, a disturbing signal for kidney cancer was identified. Patients on these jabs were approximately one-third more likely to develop kidney cancer than non-users, with the risk being highest among those under 65 and individuals who were overweight.

Kidney cancer is a 'silent killer,' often lacking symptoms until it reaches advanced stages. It is one of the fastest-rising cancers in Britain and the US, with cases climbing sharply in younger adults; those born in 1990 are up to three times more likely to develop the disease than those born in the 1950s. This trend is partly attributed to rising obesity and high blood pressure. Dr. Hao Dai, who led the research, expressed concern, stating, 'We need to do another observational study to confirm that these drugs increase the risk. But from my point of view, it might be that the drugs raise the risk of some types of kidney cancer.' Theories for this potential link include severe side effects like nausea, vomiting, and dehydration, which could lead to acute kidney injury. Another speculative theory suggests that constant stimulation of GLP-1 receptors in the kidneys, which these drugs target, might cause cells to grow uncontrollably, or that rapid weight loss and metabolic shifts could play a role.

However, experts urge caution. Professor Paul Pharoah noted that 'the presence of an association does not mean that the association is a causal one.' Dr. Stephen Lawrence highlighted the small absolute risk, citing 'about six extra cases for every 10,000 patients treated over a year,' considering it 'still a drop in the ocean against other health benefits.' He emphasized the need for further research to draw firm conclusions, especially given the drugs' proven benefits in cutting the risk of heart attacks, strokes, and kidney disease, in addition to dramatic weight loss.

Beyond cancer concerns, users of GLP-1 drugs are increasingly reporting significant dental problems. Hope Lancaster Colquhoun, a 42-year-old from the UK, experienced a dramatic nine-stone weight loss with Mounjaro after a diabetes diagnosis. However, she also noticed a distressing side effect: multiple teeth snapping in half, leading to the extraction of seven teeth and a £3,700 expense, necessitating dentures for life. Her story reflects a growing trend, with online forums filled with similar accounts of receding gums, yellowing teeth, bad breath, gum disease, and tooth loss.

Dental experts attribute these issues, often dubbed 'Ozempic teeth' or 'Ozempic mouth,' primarily to two mechanisms. Firstly, the drugs slow the rate of digestion to promote satiety, causing food to remain in the stomach longer. This increases the risk of stomach acid refluxing into the mouth, which weakens and dissolves tooth enamel, making teeth highly susceptible to decay. Secondly, the drugs can lead to dry mouth, or xerostomia, by dampening appetite and reducing the sensation of thirst, causing patients to drink less water and produce less saliva. Saliva is crucial for protecting teeth by neutralizing acid, repairing enamel, and providing immune defenses against bacteria; its absence accelerates plaque buildup and gum disease. Other contributing factors may include underlying gum disease, weakened enamel, genetic predisposition, nutritional gaps from rapid weight loss, and poor dietary choices, such as opting for softer, processed foods that can reduce facial muscle strength and impact dental arches.

The severity of these dental issues has even led to legal action. Jaclyn Bjorklund, a patient from Louisiana, filed a lawsuit against Mounjaro manufacturer Eli Lilly and Ozempic manufacturer Novo Nordisk, claiming the jabs caused gastroparesis, leading to such severe vomiting that some of her teeth fell out. Despite her dental struggles, Hope Lancaster Colquhoun still views the jab as 'life-changing' and encourages others to consider it. Eli Lilly, in response to such reports, stated: 'Patient safety is Lilly’s top priority, and we take any reports regarding patient safety extremely seriously. Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine. Lilly is committed to continually monitoring, evaluating and reporting safety data to ensure the latest information is available for regulators and prescribers.'

In conclusion, while GLP-1 weight-loss drugs offer substantial benefits in managing obesity and reducing the risk of conditions like heart attacks and strokes, as well as an overall reduced cancer risk, emerging concerns regarding specific adverse effects on kidney health and dental integrity warrant ongoing vigilance, further research, and open communication between patients and healthcare providers.